Rolf K. Hultsch

Interventional Radiology
9003 E Shea Blvd
Scottsdale, AZ 85260

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 20, 2021
Showing 1-1 of 1

Last Updated: 09/26/2026